WO1995033058A1 - Codage genique pour le recepteur modifie de la proteine morphogenetique osseuse - Google Patents
Codage genique pour le recepteur modifie de la proteine morphogenetique osseuse Download PDFInfo
- Publication number
- WO1995033058A1 WO1995033058A1 PCT/JP1995/001009 JP9501009W WO9533058A1 WO 1995033058 A1 WO1995033058 A1 WO 1995033058A1 JP 9501009 W JP9501009 W JP 9501009W WO 9533058 A1 WO9533058 A1 WO 9533058A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor
- bmp
- modified
- gene
- bone morphogenetic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a gene encoding a variant of a bone morphogenetic factor receptor, a variant of a bone morphogenetic factor receptor expressed thereby, and a use thereof. More specifically. A gene encoding a variant related to the extracellular region of the bone morphogenetic receptor, and expressed therefrom, for diagnosis of various bone diseases, screening of bone morphogenesis-related substances, purification of bone morphogenetic factor, etc. Useful bone morphogenetic receptor variants. Background art
- Bone tissue is a dynamic organ that undergoes formation and resorption for a lifetime. Osteoblasts derived from mesenchymal cells play a major role in bone formation, and osteoclasts derived from the hematopoietic system play a major role in bone resorption.A mechanism called remodeling replaces old bones with new bones. The strength is maintained. Bone in the resting phase is first absorbed by osteoclasts. The bone resorbed by the osteoclasts is then repaired by the osteoblasts. '
- osteoinductive factor the factor that induces immature cells to differentiate into osteoblasts
- osteogenic factor the factor that promotes bone formation by osteoblasts
- retinoic acid belongs to the former, and TGF- / 9 is considered to belong to the latter.
- BMP bone Morphogenetic Protein
- mRNA has been confirmed to be expressed not only in bone tissues such as teeth and bones, but also in the heart, brain, lungs, liver, kidneys, skin, hair roots, and the like. It is thought to have an important role in mesenchymal action, and its biological role has been noted. At the protein level, it has been confirmed to be present in bone tissue, tooth tissue, and osteosarcoma.
- Japanese Patent Publication No. 2-5000041 discloses a bone and cartilage induction composition and an osteoinduction composition containing BMP as an active ingredient.
- Japanese Patent Application Laid-Open No. 5-132324 / 26 discloses a prophylactic / therapeutic agent for osteopenic diseases as a bone tissue formation promoting agent; In Japan, a bone formation and growth polypeptide identified from bone marrow is identified; Japanese Patent Application Publication No. 5-504504 discloses that bone repair is carried out by synergistic combination with TGF- / 9. The use of bone morphogenetic proteins for the production of proteins is disclosed.
- BMP bone growth factor
- osteopenic diseases such as osteoporosis. It is expected to be used as a new tumor marker in osteosarcoma, a therapeutic agent for BMP-producing tumors, and a therapeutic agent for oral diseases.
- BMP was named in the 1960's as a proteinaceous molecule present in the bone matrix that causes ectopic bone formation. It has been shown to be one of the members of the TG F- ⁇ family whose structure was known (Proc. Natl. Acad. Sci. USA 81, 371-375; Progress Growth Factor Research II, 267-280, 1989). Also, as a protein belonging to the same family, activin and the like have been known so far (Nature 231, 776-778, 1986; Nature 231, 779-782, 1986).
- BMP proteins purified from bone matrix 2 to 8 belong to the TG F- / 9 family, and to date, these seven BMPs are similar to the three groups. Can be classified by gender. That is, there are three types: a group consisting of 2 and 4, a group consisting of 3, and a group consisting of 5, 6, 7, and 8.
- BMP is a factor that promotes osteoinduction and bone formation, and has a close relationship with the onset and healing of bone tissue disorders. Is important.
- substances having an action similar to BMP There is also a need for a method for screening substances that antagonize BMP and BMP, and a simple method for purifying BMP.
- BMP-specific antibodies are generally prepared and applied, but such antibodies have not been known until now. It is thought that this is due to the difficulty in producing antibodies because the peptide is very well preserved during the evolution process, even across species differences. Therefore, there has been a widespread demand for a technique for solving the above-mentioned problems using substances other than antibodies.
- the present inventors have intensively studied a substance capable of specifically reacting with BMP, and as a result, they have found that the problem can be solved by using a modified BMP receptor.
- the present inventors have been conducting research on the BMP gene for many years (Biochem. Biophys. Res. Commun. 186, 1487-1992; Growt h Factor 7, 233-240; Growth Factors 8 , 165-172, 1993; Growth Factors 10, 173-176, 1993; Biochem. J., 298, 275-280, 1993). Abstracts 2175, 1992; 3209, 1993).
- the selective receptor has not been known before, but recently, studies by US companies and the present inventors have revealed that two types of receptors for BMP (BMP 2 and 4) It was isolated and its properties were clarified (International Symposium on Molecular Pharmacology 1994, p27).
- BMP performs its function by binding to a receptor expressed on the cell surface, similar to a cell growth factor well known in the art.
- Receptors are generally characterized by three structural regions: extracellular region, intracellular region, and transmembrane region.
- BMP receptor is also extracellular, which is rich in cysteine residues. It consists of a domain and one transmembrane domain, and the intracellular domain has been found to be a serine threonine kinase common to TGF- ⁇ families.
- an object of the present invention is to provide a variant obtained by adding an epitope tag to an extracellular region of a BMP receptor, a gene encoding the variant, and a use of the variant. Disclosure of the invention
- the present invention made to solve the above-mentioned problems includes a gene encoding a modified BMP receptor shown below, a modified BMP receptor obtained by expressing the gene, and uses of the variant. About.
- a modified BMP receptor gene in which a gene encoding the extracellular region of the BMP receptor and a gene encoding an antigenic determinant recognized by an antibody are linked.
- a modified BMP receptor comprising the amino acid sequence shown in SEQ ID NO: 2 or an amino acid sequence containing the sequence.
- a therapeutic agent for bone disease comprising the BMP receptor variant described in 4 or ⁇ ⁇ ⁇ above as an active ingredient.
- FIG. 1 is a diagram schematically showing a process of subcloning myc-sm BMPR digested with a restriction enzyme Ec0RI into an expression vector-pc DNA Iamp. is there.
- FIG. 2 is a diagram showing the results of SDS-electrophoresis of a produced culture solution and a sample obtained by purifying it with an affinity column in Example 3.
- FIG. 3 is a diagram showing the competitive inhibition of a modified BMP receptor against BMP in Example 4.
- FIG. 4 is a diagram showing the results of measuring BMP using a modified BMP receptor in Example 5.
- the gene encoding the modified BMP receptor according to the present invention is a gene in which a gene encoding the extracellular region of the BMP receptor and a gene encoding an antigenic determinant recognized by an antibody are linked.
- an antigenic determinant epitope tag method
- Identification and identification of proteinaceous substances is widely known as the epitope tag method. Such a method is described in detail in, for example, Method in Enzymology 194, pp. 509, 1991 as a method for adding an antigenic determinant.
- the above-described gene of the present invention is a gene used to express a protein in which an antigenic determinant recognizable by an antibody has been added to the extracellular region of a BMP receptor, and the protein expressed by such a gene is an antibody. Makes it identifiable.
- epitope tag The antigenic determinant recognized by the above antibody (hereinafter referred to as “epitope tag” for convenience) is not particularly limited, and includes various types of epitope tags described in the above-mentioned literatures.
- Amino acid sequence U Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-
- the amino acid sequence Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala) that is recognized by the anti-influenza hemagglutinin antibody (12CA5) Is exemplified.
- a peptide expressed by the 1acZ gene can also be used as an epitope tag, and in this case, an anti-3-galactosidase antibody is used as the antibody.
- a gene encoding the extracellular region of the BMP receptor for example, a gene obtained by cleaving the BMP receptor gene at the 3 ′ base from the 5 ′ terminal
- the gene encoding the epitope tag described above are linked.
- a gene encoding the extracellular region of the BMP receptor may include an anti-myc monoclonal antibody (9E1 0)
- 9E1 0 A gene obtained by adding a gene encoding the above amino acid sequence to be the antigenic determinant to the 3 ′ end of the gene encoding the extracellular region is exemplified.
- the gene encoding the BMP receptor can be prepared from mRNA of the BMP receptor. More specifically, BMP receptor mRNA is extracted from organs, tissues, cells, etc., which express the BMP receptor by a conventional method such as the phenol method, the guanidinium thiosinate method, or the like. It can be obtained by purification using a purification means such as column.
- cDNA of the BMP receptor is prepared by a conventional method such as a random primer method.
- a primer oligonucleotide for PCR assumed from that portion is synthesized.
- the above cDNA is re-amplified by PCR.
- the cDNA amplified by the PCR method is separated and extracted by gel electrophoresis such as agarose gel electrophoresis or acrylamide gel electrophoresis.
- the nucleotide sequence of the extracted DNA fragment is determined according to a conventional method such as the M13 didequine method or using a commercially available nucleotide sequencing kit or the like, and the nucleotide sequence of the TGF-i9 activin receptor is determined.
- a DNA fragment having a different sequence from the DNA fragment is selected.
- cDNA encoding the full length of the BMP receptor can be isolated from the cDNA library.
- the nucleotide sequence can be determined according to the above.
- the gene of the present invention in which the gene encoding the extracellular region of the BMP receptor is linked to the gene encoding the epitope tag encodes the full length of the BMP receptor prepared as described above.
- c Insert the DNA into an appropriate vector and The vector is propagated by the PCR method using appropriate primers containing the nucleotide sequence encoding the tag and the sequence complementary to the translation termination sequence, and the amplified gene is isolated and purified according to a conventional method. By doing so, the gene of the present invention can be obtained.
- the cDNA encoding the full length of the BMP receptor is cleaved with an appropriate restriction enzyme, a DNA fragment encoding the extracellular region is separated, and a DNA fragment encoding the epitope is bound to this. Can also be prepared.
- the modified BMP receptor of the present invention is a protein in which an epitope tag is bound to an extracellular region of a BMP receptor, and the above-described gene encoding the extracellular region of the BMP receptor and the epitop tag are linked to each other. It can be prepared by expressing the gene to which the coded gene is linked by genetic engineering. Such genetic engineering expression can be performed according to a conventional method.
- a gene in which a gene encoding the extracellular region of the BMP receptor is linked to a gene encoding the epitope tag a DNA fragment obtained by digesting the DNA with an appropriate restriction enzyme is incorporated into an appropriate expression vector, and an appropriate host for the vector (for example, bacteria such as Escherichia coli and Bacillus subtilis, yeast, mold, animal and plant cultured cells) ), And transforming the transformant, and culturing the transformant.
- a modified BMP receptor can be obtained from the culture supernatant (or the supernatant after crushing the cultured cells).
- the modified BMP receptor thus obtained can be purified by a conventional method such as dialysis, salting out, ion exchange chromatography, or gel filtration chromatography, but has bound an antibody recognizing an epitope tag.
- affinity chromatography By performing affinity chromatography using a carrier, purification can be performed easily and highly.
- modified BMP receptor of the present invention can also be prepared by a solid phase synthesis method of a peptide based on an amino acid sequence deduced from a base sequence.
- modified BMP receptor of the present invention as long as it is substantially the same, a part of the amino acid sequence is deleted or substituted with another amino acid, or another amino acid sequence is replaced with another amino acid sequence. It may be inserted, one or two or more amino acids may be bound to the N-terminal and the C-terminal, or the sugar chain may be added, deleted or substituted.
- the specific reaction of the modified BMP receptor of the present invention with BMP was revealed by a competitive reaction with BMP, as shown in Examples described later.
- MC 3 T 3 cells derived from mouse calvaria are known to differentiate into osteoblasts, and the process is promoted by BMP. It is known that alkaline phosphatase (ALPase) activity increases as an index (protein, nucleic acid, enzyme, No. 2, 186, 1988).
- ALPase alkaline phosphatase
- the modified BMP receptor of the present invention has the property of specifically reacting with BMP in the extracellular region of the BMP receptor and specifically reacting with the antibody recognizing it in the epitope tag portion.
- the BMP measurement method of the present invention utilizes such characteristics to measure (quantitatively and qualitatively) BMP by a method similar to an immunological assay. For example, a BMP-containing sample is taken in a microplate, BMP is adsorbed to the plate, and if necessary, blocked with serum albumin (BSA) or the like, and then the modified BMP receptor of the present invention is added. After binding to BMP, and then adding a labeled antibody and binding to the epitope tag of the variant, BMP can be measured by measuring the labeling activity. In this method, instead of the labeled antibody, a non-labeled antibody may be reacted, followed by a reaction with a labeled secondary antibody or labeled protein A.
- BSA serum albumin
- the label is not particularly limited, enzymes conventionally used in immunoassays (eg, passoxidase, alkaline phosphatase, / 9-galactosidase, etc.), radioactive substances (eg, , 125 I, 32 P, 3 H, etc.), fluorescent substances and the like.
- enzymes conventionally used in immunoassays eg, passoxidase, alkaline phosphatase, / 9-galactosidase, etc.
- radioactive substances eg, , 125 I, 32 P, 3 H, etc.
- the method for measuring BMP of the present invention is not limited to the above method, and various methods known as immunological measurement methods such as a competition method can be applied, and such methods are well known to those skilled in the art. It is.
- BMP can be measured quickly, with high sensitivity and high precision, and the quantitativeness has been confirmed at least between 1 and 100 ng.
- the advantage of the assay is that it is difficult to distinguish between the precursor and the active form in the immunoassay, but in this assay, it can be detected as a physiologically significant molecule It is mentioned that it is.
- the modified BMP receptor of the present invention when used, it has a screening activity of a substance having a biological activity similar to BMP or an action of antagonizing BMP by a method according to the above-described assay method.
- Substance screening can be performed. For example, a complex in which a labeled antibody is bound to the epitope tag of the modified BMP receptor of the present invention is prepared, and a test substance is reacted with the above-mentioned complex. It is presumed that the substance has a physiological activity similar to that of.
- the modified BMP receptor of the present invention specifically binds to BMP, it can be used for the isolation and purification of BMP, and the method for purifying BMP of the present invention utilizes such properties.
- a carrier in which an antibody recognizing an epitope tag is chemically or physically bound to an insoluble carrier is prepared, and the modified BMP receptor of the present invention is brought into contact with the carrier to immobilize it.
- BMP can be immobilized on the carrier by contacting the carrier with a sample containing BMP, and then BMP can be purified by eluting the BMP with an appropriate eluate.
- a conventional carrier such as Sepharose can be used, and the binding of the antibody to the insoluble carrier can also be performed by a conventional method such as a method using a formylated cellulose gel.
- the above-mentioned purification method can be carried out by any of the column method and the batch method.
- the method for purifying BMP of the present invention is not limited to the above method, and various methods known as affinity chromatography can be applied, and such methods are well known to those skilled in the art. .
- BMP can be simply, rapidly and highly purified.
- the therapeutic agent for bone disease of the present invention comprises a modified BMP receptor as an active ingredient.
- the modified BMP receptor of the present invention reacts specifically and competitively with BMP. It is useful for the treatment and prevention of BMP-related bone diseases such as BMP-producing tumors.
- the above-mentioned therapeutic agent can be administered in various formulation forms (for example, liquid, solid, capsule, etc.), but generally, only the modified BMP receptor which is an active ingredient or together with a conventional carrier.
- injectable or oral. The injection can be prepared by a conventional method. For example, after dissolving the modified BMP receptor in an appropriate solvent (eg, sterilized water, buffer solution, physiological saline, etc.), a filter, etc. It can be prepared by filtering and sterilizing with, and filling in a sterile container.
- Oral drugs include, for example, tablets, granules, fine granules, powders, soft or hard capsules, liquids, emulsions, suspensions, syrups, etc. It can be prepared according to a conventional method for chemical conversion.
- the content of the modified BMP receptor in the preparation can be appropriately adjusted depending on the dosage form, applicable disease and the like.
- a stabilizer is preferably added.
- the stabilizer include albumin, globulin, gelatin, glycine, mannitol, glucose, dextran, sorbitol, ethylene glycol and the like.
- the preparation of the present invention may contain additives necessary for preparation, for example, excipients, dissolution aids, antioxidants, soothing agents, isotonic agents and the like.
- a liquid preparation it is desirable to store it by removing the water content by cryopreservation or lyophilization.
- the lyophilized preparation is used after reconstitution by adding distilled water for injection at the time of use.
- the therapeutic agent for bone disease of the present invention can be administered by an appropriate administration route depending on the formulation.
- the dose is appropriately adjusted according to the patient's condition, age, weight, and the like. Industrial applicability
- a gene encoding a modified BMP receptor is provided, and a modified BMP receptor can be efficiently obtained by expressing the gene.
- BMP can be measured easily and with high precision, and a substance having a biological activity similar to BMP or a substance that antagonizes BMP can be screened.
- BMP can be rapidly and highly purified.
- the modified BMP receptor specifically binds to BMP, it is also useful as a therapeutic agent for bone disease for treating or preventing a bone disease caused by BMP. Therefore, the modified BMP receptor of the present invention can be widely used as a purification reagent for BMP, a diagnostic reagent for various diseases related to BMP, a research reagent, a medical drug and the like.
- Synthesis of these synthetic oligonucleotides was carried out according to a conventional method using an apparatus manufactured by Milligen Biosearch.
- the nucleotide sequence of the amplified gene fragment was determined, and a gene fragment having a sequence different from that of the TGF- ⁇ activin receptor was identified.
- mTFRl1 a gene that completely encodes the desired mouse BMP receptor was isolated from one mouse cDNA library. Among the clones obtained, a clone of 3.9 kb in total length, designated as mTFRl1, was found to be a mouse BMP receptor.
- mTFRl1 a clone of 3.9 kb in total length
- Example 3 Using the same method as in Example 1 except that total RNA produced from the early embryo of Xenopus laevis was used, a fragment of the Xenopus BMP receptor gene was identified and named xTFRl1. Using this gene fragment as a probe, a gene completely encoding the Xenopus BMP receptor was isolated from a cDNA library of the Xenopus stage 3-5.
- Example 3 Using the same method as in Example 1 except that total RNA produced from the early embryo of Xenopus laevis was used, a fragment of the Xenopus BMP receptor gene was identified and named xTFRl1. Using this gene fragment as a probe, a gene completely encoding the Xenopus BMP receptor was isolated from a cDNA library of the Xenopus stage 3-5.
- Example 2 the mT'F R11cDNA obtained in Example 1 was transformed with Bluescript KS (-) vector. PCR was performed using this vector and oligonucleotides 3 and 4, and the anti-oncogene myc antibody (9) was added 3 'to the gene sequence corresponding to the extracellular region of the BMP receptor.
- SEQ ID NO: 1 shows the nucleotide sequence of the gene fragment (referred to as mycs-mBMPR).
- mycs-mBMPR the underlined portion is the sequence encoding the epitope tag.
- SEQ ID NO: 2 shows the amino acid sequence of the modified BMP receptor deduced from the nucleotide sequence.
- the modified BMP receptor of the present invention was obtained by transforming COS 7 cells with the above vector by the DEAE-dexTRAN method and expressing the transformed cells.
- 1 ⁇ 10 B COS 7 cells were cultured in a culture dish with a bottom area of 600 cm 2 using Dulbecco's modified medium.
- Mix 1 O ⁇ g of DNA with 3 ml of DEAE-dextran add to a culture dish, leave at room temperature for 15 minutes, wash, and culture for 1 day in Dulbecco's modified medium containing 10% serum did. After that, the medium was replaced with a serum-free Dulbecco's modified medium, and the cells were further cultured for 3 days to collect a total of 5 L of the culture supernatant.
- the collected culture supernatant was concentrated by ultrafiltration with a filter having a molecular weight of 100,000 D (Asahi Kasei), and an equal volume of Tris-based buffer (20 mM Tris-HCl (pH 7.4) /0.15 NaCl, TBS buffer) and adsorbed to an affinity column (5 mJL) prepared by binding the anti-oncogene myc monoclonal antibody 9E10 to a carrier (Affigel).
- the adsorbed fraction was eluted with a citrate buffer having a pH of 3.0, and after elution, dialyzed against a Tris-based buffer to obtain the modified BMP receptor of the present invention. saved.
- FIG. 2 shows the results of analysis by SDS-electrophoresis.
- the fraction adsorbed on the column was only a protein having a molecular weight of 18 KD, as compared with that before purification, which was in good agreement with the theoretical molecular weight. From this, it was confirmed that the modified BMP receptor could be purified by affinity chromatography to which the antibody was bound.
- Microplate 4 8 holes were seeded 1 0 4 MC 3 T 3 cells per well (medium: 1 0 containing 0% 83: MEM medium). After culturing for 2 days, the medium was replaced with a medium containing 10 ng Zm1 of BMP, and culturing was performed for 48 hours. At this time, the modified BMP receptor prepared in Example 1 was added at a concentration of 10 or 5 OngZml, and the lipophosphatase (ALPase) activity was compared with the group without BMP.
- ALPase lipophosphatase
- ALPase activity To measure the ALPase activity, first discard the culture supernatant, wash well with a phosphate buffer, and then use a p-nitrotropenol solution (0.56 M 2-amino-2-methylpropanol) as a chromogenic substrate. All, ImM MgC, ⁇ sodium p-nitrophenyl phosphate) were added to each well, and after reacting for 1 hour, the absorbance at 405 nm was measured.
- FIG. 3 shows the results. As shown in FIG. 3, inhibition of BMP activity was observed by adding the modified BMP receptor.
- Example 5 shows the results. As shown in FIG. 3, inhibition of BMP activity was observed by adding the modified BMP receptor.
- Fig. 4 shows the results.
- Ab means the primary antibody.
- BMP can be quantified by using the modified BMP receptor of the present invention.
- Sequence type nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95919640A EP0771877A4 (en) | 1994-05-26 | 1995-05-25 | MODIFIED MORPHOGENIC PROTEIN RECEPTOR IN BONE CODING GENE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6137935A JPH07313169A (ja) | 1994-05-26 | 1994-05-26 | 骨形成因子受容体改変体の遺伝子 |
JP6/137935 | 1994-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995033058A1 true WO1995033058A1 (fr) | 1995-12-07 |
Family
ID=15210146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/001009 WO1995033058A1 (fr) | 1994-05-26 | 1995-05-25 | Codage genique pour le recepteur modifie de la proteine morphogenetique osseuse |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0771877A4 (ja) |
JP (1) | JPH07313169A (ja) |
CA (1) | CA2191321A1 (ja) |
WO (1) | WO1995033058A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8338377B2 (en) | 2009-03-30 | 2012-12-25 | Acceleron Pharma Inc. | BMP-ALK3 antagonists and uses for promoting bone growth |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60032614D1 (de) * | 1999-08-25 | 2007-02-08 | Ambergen Inc | Verfahren zur erkennung, analyse und isolierung von freiwerdenden proteinen |
JP2008504850A (ja) * | 2004-06-16 | 2008-02-21 | アフィナジー, インコーポレイテッド | 整形外科インプラントの表面に対する標的分析物の特異的接着を促進するためのifbm |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248554B1 (en) * | 1993-11-24 | 2001-06-19 | The Procter & Gamble Company | DNA sequence coding for a BMP receptor |
-
1994
- 1994-05-26 JP JP6137935A patent/JPH07313169A/ja active Pending
-
1995
- 1995-05-25 WO PCT/JP1995/001009 patent/WO1995033058A1/ja not_active Application Discontinuation
- 1995-05-25 CA CA002191321A patent/CA2191321A1/en not_active Abandoned
- 1995-05-25 EP EP95919640A patent/EP0771877A4/en not_active Withdrawn
Non-Patent Citations (3)
Title |
---|
MOL. CELL. BIOL., (1994), Vol. 14, No. 9, KOENIG B.B. et al., "Characterization and Cloning of a Receptor for BMP-2 and BMP-4 from NIH 3T3 Cells", pages 5961-74. * |
PROC. NATL. ACAD. SCI. U.S.A., (1994), Vol. 91, No. 22, SUZUKI A., "A Truncated Bone Morphogenetic Protein Receptor Affects Dorsal-Ventral Patterning in the Early Xenopus EMbryo", pages 10255-9. * |
See also references of EP0771877A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8338377B2 (en) | 2009-03-30 | 2012-12-25 | Acceleron Pharma Inc. | BMP-ALK3 antagonists and uses for promoting bone growth |
US8945877B2 (en) | 2009-03-30 | 2015-02-03 | Acceleron Pharma, Inc. | Polynucleotides encoding BMP-ALK3 antagonists |
US9914762B2 (en) | 2009-03-30 | 2018-03-13 | Acceleron Pharma Inc. | BMP-ALK3 antagonists and uses for promoting bone growth |
Also Published As
Publication number | Publication date |
---|---|
JPH07313169A (ja) | 1995-12-05 |
EP0771877A1 (en) | 1997-05-07 |
EP0771877A4 (en) | 1999-04-14 |
CA2191321A1 (en) | 1995-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3045398B2 (ja) | 蛋白質、dnaおよびその用途 | |
KR100631766B1 (ko) | 폴리펩티드, 그 폴리펩티드를 암호화하는 cDNA 및그들의 용도 | |
Hallahan et al. | Importance of asparagine-61 and asparagine-109 to the angiogenic activity of human angiogenin | |
JPH04505151A (ja) | 骨形成因子 | |
JP2002523035A (ja) | 49個のヒト分泌タンパク質 | |
JP2001524814A (ja) | 28種類のヒト分泌タンパク質 | |
JP2002509432A (ja) | 哺乳類サイトカイン様因子7 | |
JP2002508167A (ja) | 110個のヒト分泌タンパク質 | |
JPH06505965A (ja) | β型トランスフォーミング成長因子 | |
JPH06502538A (ja) | 上皮細胞成長因子(egf)との相同性をもつヘパリン結合性マイトジェン | |
JP2001521383A (ja) | 20個のヒト分泌タンパク質 | |
JP2002512521A (ja) | 32個のヒト分泌タンパク質 | |
CA2017466A1 (en) | Bone calcification factor | |
JP2002537796A (ja) | ヒトグリコシル化酵素 | |
JP2003524366A (ja) | 64個のヒト分泌タンパク質 | |
JP2003525566A (ja) | 125個のヒト分泌タンパク質 | |
US6372890B1 (en) | Water-soluble polypeptides | |
JP2001519179A (ja) | 53個のヒト分泌タンパク質 | |
JPH11506917A (ja) | 線維芽細胞増殖因子11 | |
WO1995033058A1 (fr) | Codage genique pour le recepteur modifie de la proteine morphogenetique osseuse | |
EP0568539A1 (en) | Soluble mannose receptor peptides | |
JP2003521215A (ja) | 83個のヒト分泌タンパク質 | |
JPH11507504A (ja) | 線維芽細胞増殖因子13 | |
JPH05271291A (ja) | 機能性ポリペプチド | |
JP2002508166A (ja) | ヒトDendriacおよびBrainiac−3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2191321 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995919640 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1997 750111 Country of ref document: US Date of ref document: 19970106 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1995919640 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995919640 Country of ref document: EP |